Virtualscopics Inc (VSCP) 4.04 $VSCP BioTelemet
Post# of 273258
Posted On: 09/03/2016 1:05:34 AM
Virtualscopics Inc (VSCP) 4.04 $VSCP
BioTelemetry, Inc. Announces the Completion of Its Acquisition of VirtualScopics, Inc.
GlobeNewswire - Wed May 11, 8:25AM CDT
BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that it has completed its acquisition of VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions. The acquisition comes after the successful completion of the all cash tender offer for all outstanding common and preferred shares of VirtualScopics. The total purchase consideration was approximately $15.0 million, net of cash and debt acquired.
VSCP: 4.04 (+0.01), BEAT: 18.82 (+0.12)
BioTelemetry, Inc. Announces Results of Tender Offer for Shares of VirtualScopics, Inc.
GlobeNewswire - Tue May 10, 7:05AM CDT
BioTelemetry, Inc. (NASDAQ: BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that the tender offer of its wholly owned subsidiary, BioTelemetry Research Acquisition Corporation ("Offeror"
, to purchase all outstanding common and preferred shares of VirtualScopics, Inc. ("VirtualScopics"; (NASDAQ:VSCP) at an offer price of $4.05 per share for VirtualScopics' common stock, $336.30 per share for VirtualScopics' Series A and Series B Convertible Preferred Stock and $920.00 per share for VirtualScopics' Series C-1 Convertible Preferred Stock, expired as scheduled at 5:00 p.m., New York City time, on Monday, May 9, 2016, and was not extended.
VSCP: 4.04 (+0.01), BEAT: 18.82 (+0.12)
BioTelemetry, Inc. Commences Previously Announced Tender Offer to Acquire VirtualScopics, Inc.
GlobeNewswire - Fri Apr 08, 3:05PM CDT
BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that its wholly owned subsidiary, BioTelemetry Research Acquisition Corporation ("Offeror", is commencing a cash tender offer to purchase all outstanding common and preferred shares of VirtualScopics, Inc. ("VirtualScopics" (NASDAQ:VSCP) at an offer price of $4.05 per share for VirtualScopics' common stock, $336.30 per share for VirtualScopics' Series A and Series B Convertible Preferred Stock and $920.00 per share for VirtualScopics' Series C-1 Convertible Preferred Stock. The tender offer is being made pursuant to an Offer to Purchase, dated April 8, 2016, and in connection with the Agreement and Plan of Merger, dated March 25, 2016, among BioTelemetry, Offeror and VirtualScopics, which BioTelemetry and VirtualScopics previously announced on March 25, 2016.
VSCP: 4.04 (+0.01), BEAT: 18.82 (+0.12)
VirtualScopics, Inc. Cancels Conference Call Due To Recent Announcement Of The Definitive Agreement With BioTelemetry, Inc.
PR Newswire - Tue Mar 29, 7:50AM CDT
VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions, today announced it will not hold its conference call, or provide its webcast, previously scheduled for Wednesday, March 30, 2016 at 8:30 a.m. ET.
VSCP: 4.04 (+0.01), BEAT: 18.82 (+0.12)
VIRTUALSCOPICS INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to BioTelemetry, Inc.
BusinessWire - Mon Mar 28, 2:54PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of VirtualScopics Inc. ("VirtualScopics" (NasdaqCM: VSCP) concerning the sale to BioTelemetry, Inc. Under the terms of the agreement, VirtualScopics common shareholders will only receive $4.05 per share, which is virtually no premium over the 52-week high and lower than at least one analyst's estimated value of $7.00 per share. Series A and Series B Convertible Preferred Stock shareholders will receive $336.30 per share and Series C-1 Convertible Preferred Stock holders will receive $920.00 per share. The tender offer is expected to commence on April 11, 2016 and will be open for a minimum of 20 business days.
VSCP: 4.04 (+0.01), BEAT: 18.82 (+0.12)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation as to Whether the Sale of VirtualScopics Inc. to BioTelemetry, Inc. is Fair to Shareholders -- VSCP
ACCESSWIRE - Mon Mar 28, 9:14AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
VSCP: 4.04 (+0.01), BEAT: 18.82 (+0.12)
BioTelemetry, Inc. Signs Definitive Agreement to Acquire VirtualScopics, Inc.
GlobeNewswire - Fri Mar 25, 10:30AM CDT
BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, and VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions, announced today that the two companies have entered into a definitive agreement whereby BioTelemetry will acquire VirtualScopics.
VSCP: 4.04 (+0.01), BEAT: 18.82 (+0.12)
VirtualScopics, Inc. Announces Amendment to Exclusive Marketing Agreement with PPD; Provides Additional Opportunities to Develop New Business Relationships
PR Newswire - Fri Jan 22, 8:00AM CST
VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, today announced that it is amending its alliance agreement with PPD, a contract research organization (CRO), to eliminate the marketing exclusivity portion of the agreement, effective April 11, 2016. The agreement originally signed in 2010, which focused on oncology trials and was later expanded to include other therapeutic areas, restricted VirtualScopics and PPD from co-marketing with each other's competitors. Under the amended agreement, VirtualScopics and PPD will no longer be restricted by exclusive co-marketing. Going forward, they will continue to collaborate on joint imaging projects already underway, as well as those in the current backlog. In addition, they will continue to work together to win new business for their alliance.
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. Promotes Ronald Way to Chief Operating Officer
PR Newswire - Thu Dec 17, 12:02PM CST
VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, today announced that Ronald Way, 60, has been promoted to chief operating officer (COO). Mr. Way joined VirtualScopics in January 2011 as director of operations and was promoted to vice president of operations in August 2014. Mr. Way will be responsible for leading all functions required to deliver superb clinical trial imaging solutions to the company's customers using regulatory compliant processes. Mr. Way has contributed to the increased customer loyalty retention rate over the past few years.
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. Reports 2015 Third Quarter Revenues Increase 18% From Prior Year Period And Company Achieves Positive Adjusted EBITDA
PR Newswire - Thu Oct 29, 3:01PM CDT
VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions, today reported financial results for the third quarter and nine months ended September 30, 2015.
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. to Host Third Quarter 2015 Earnings Conference Call and Webcast Live on Thursday, October 29, 2015
ACCESSWIRE - Wed Oct 28, 3:15PM CDT
ROCHESTER, NY / ACCESSWIRE / October 28, 2015 / VirtualScopics, Inc. (NASDAQ: VSCP) will host a conference call and live webcast to discuss the results of the third quarter 2015, to be held Thursday, October 29, 2015 at 4:30 PM Eastern Time.
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. Schedules Third Quarter 2015 Financial Results Press Release, Conference Call And Webcast
PR Newswire - Wed Oct 14, 7:00AM CDT
VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions, today announced it will report its third quarter 2015 financial results at the 4:00 p.m. ET market close on Thursday, October 29, 2015. Eric T. Converse, president and chief executive officer, and Jim Groff, chief financial officer, will host a conference call and webcast to discuss the company's financial results and provide a business update at 4:30 p.m. ET that afternoon. The conference call and webcast information are as follows:
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. Reports 2015 Second Quarter And Six Months Financial Results; Revenues Increase 14% From 2014 Second Quarter And 17% Above The Six Months Reported In 2014
PR Newswire - Tue Aug 11, 3:01PM CDT
VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions, today reported financial results for the second quarter and six months ended June 30, 2015. Revenues for the second quarter of 2015 rose 14% to $3,019,126 compared to revenues of $2,648,747 for the comparable prior year period. The company reported a net loss for the second quarter of 2015 of $546,992, or $0.20 loss per share, representing a 25% improvement from a net loss of $731,531, or $0.26 loss per share, reported in the second quarter of 2014. Revenues for the first half of 2015 rose 17% to $5,833,568 compared to revenues of $5,001,732 for the comparable prior year period. The company reported a net loss for the first half of 2015 of $1,099,664, or $0.40 loss per share, representing a 20% improvement from a net loss of $1,377,904, or $0.49 loss per share, reported in the first half of 2014.
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. to Host Second Quarter 2015 Earnings Conference Call and Webcast Live on Tuesday, August 11, 2015
ACCESSWIRE - Mon Aug 10, 3:16PM CDT
ROCHESTER, NY / ACCESSWIRE / August 10, 2015 / VirtualScopics, Inc. (NASDAQ: VSCP) will host a conference call and live webcast to discuss the results of the second quarter 2015, to be held Tuesday, August 11, 2015 at 4:30 PM Eastern Time.
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call And Webcast
PR Newswire - Tue Jul 28, 7:00AM CDT
VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, today announced that it will report its second quarter 2015 financial results at the 4:00 p.m. ET market close on Tuesday, August 11, 2015. Eric T. Converse, president and chief executive officer, and Jim Groff, chief financial officer, will host a conference call and webcast to discuss the company's financial results and provide a business update at 4:30 p.m. ET that afternoon. Conference call, webcast and replay information is as follows:
VSCP: 4.04 (+0.01)
VirtualScopics and IXICO Alliance Receive Awards in Oncology and Neurodegenerative Disease
PR Newswire - Mon Jun 29, 7:00AM CDT
VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, along with IXICO plc (AIM: IXI), the brain health company, announced today the alliance has been awarded contracts with two top 15 pharmaceutical companies, one in metastatic solid tumors and one in a rare neurodegenerative disease. IXICO's TrialTracker(TM) digital platform will be deployed in both studies to collect and manage imaging data and in the neurodegeneration study, IXICO's Assessa® digital technology will be used to analyze MRI data collected from patients.
VSCP: 4.04 (+0.01)
Lion Biotechnologies Names Molly Henderson Chief Financial Officer
GlobeNewswire - Mon Jun 08, 7:00AM CDT
Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced the appointment of Molly Henderson, CPA, as chief financial officer, effective immediately.
VSCP: 4.04 (+0.01), LBIO: 7.97 (unch)
VirtualScopics, Inc. Reports Voting Results At Annual Meeting Of Shareholders; All Board Seats Renewed
PR Newswire - Fri Jun 05, 10:00AM CDT
VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, today announced that shareholders have voted for and ratified all three proposals contained in the company's 2015 proxy statement. The outcome of this morning's vote at the Annual Meeting of Shareholders is as follows:
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. To Webcast Annual Meeting Of Shareholders On June 2, 2015; Five Members Of Management To Provide Insight On Operational Excellence And Future Outlook
PR Newswire - Tue May 19, 10:39AM CDT
VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions, today announced it will webcast the 2015 Annual Meeting of Shareholders on Tuesday, June 2, 2015, beginning at 10:00 a.m. The meeting will be held at the Country Club of Rochester, 2935 East Avenue, Rochester, New York, and is open to all VirtualScopics shareholders. Information for this year's Annual Meeting, including the company's Annual Report, Form 10-K and Proxy Statement, can be found on the company's website, www.virtualscopics.com
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. To Present At The 2015 Marcum MicroCap Conference In New York City
PR Newswire - Wed May 13, 4:05PM CDT
VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, announced today that Eric Converse, president and chief executive officer, will be presenting at the Marcum MicroCap Conference, which will be held at the Grand Hyatt Hotel in New York City, on Wednesday, May 27, 2015 at 3:00 p.m. Mr. Converse will also be conducting one-on-one meetings with institutional investors that afternoon and on Thursday, May 28, 2015.
VSCP: 4.04 (+0.01)
BioTelemetry, Inc. Announces the Completion of Its Acquisition of VirtualScopics, Inc.
GlobeNewswire - Wed May 11, 8:25AM CDT
BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that it has completed its acquisition of VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions. The acquisition comes after the successful completion of the all cash tender offer for all outstanding common and preferred shares of VirtualScopics. The total purchase consideration was approximately $15.0 million, net of cash and debt acquired.
VSCP: 4.04 (+0.01), BEAT: 18.82 (+0.12)
BioTelemetry, Inc. Announces Results of Tender Offer for Shares of VirtualScopics, Inc.
GlobeNewswire - Tue May 10, 7:05AM CDT
BioTelemetry, Inc. (NASDAQ: BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that the tender offer of its wholly owned subsidiary, BioTelemetry Research Acquisition Corporation ("Offeror"
, to purchase all outstanding common and preferred shares of VirtualScopics, Inc. ("VirtualScopics"; (NASDAQ:VSCP) at an offer price of $4.05 per share for VirtualScopics' common stock, $336.30 per share for VirtualScopics' Series A and Series B Convertible Preferred Stock and $920.00 per share for VirtualScopics' Series C-1 Convertible Preferred Stock, expired as scheduled at 5:00 p.m., New York City time, on Monday, May 9, 2016, and was not extended. VSCP: 4.04 (+0.01), BEAT: 18.82 (+0.12)
BioTelemetry, Inc. Commences Previously Announced Tender Offer to Acquire VirtualScopics, Inc.
GlobeNewswire - Fri Apr 08, 3:05PM CDT
BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that its wholly owned subsidiary, BioTelemetry Research Acquisition Corporation ("Offeror"
, is commencing a cash tender offer to purchase all outstanding common and preferred shares of VirtualScopics, Inc. ("VirtualScopics" (NASDAQ:VSCP) at an offer price of $4.05 per share for VirtualScopics' common stock, $336.30 per share for VirtualScopics' Series A and Series B Convertible Preferred Stock and $920.00 per share for VirtualScopics' Series C-1 Convertible Preferred Stock. The tender offer is being made pursuant to an Offer to Purchase, dated April 8, 2016, and in connection with the Agreement and Plan of Merger, dated March 25, 2016, among BioTelemetry, Offeror and VirtualScopics, which BioTelemetry and VirtualScopics previously announced on March 25, 2016. VSCP: 4.04 (+0.01), BEAT: 18.82 (+0.12)
VirtualScopics, Inc. Cancels Conference Call Due To Recent Announcement Of The Definitive Agreement With BioTelemetry, Inc.
PR Newswire - Tue Mar 29, 7:50AM CDT
VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions, today announced it will not hold its conference call, or provide its webcast, previously scheduled for Wednesday, March 30, 2016 at 8:30 a.m. ET.
VSCP: 4.04 (+0.01), BEAT: 18.82 (+0.12)
VIRTUALSCOPICS INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to BioTelemetry, Inc.
BusinessWire - Mon Mar 28, 2:54PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of VirtualScopics Inc. ("VirtualScopics"
(NasdaqCM: VSCP) concerning the sale to BioTelemetry, Inc. Under the terms of the agreement, VirtualScopics common shareholders will only receive $4.05 per share, which is virtually no premium over the 52-week high and lower than at least one analyst's estimated value of $7.00 per share. Series A and Series B Convertible Preferred Stock shareholders will receive $336.30 per share and Series C-1 Convertible Preferred Stock holders will receive $920.00 per share. The tender offer is expected to commence on April 11, 2016 and will be open for a minimum of 20 business days. VSCP: 4.04 (+0.01), BEAT: 18.82 (+0.12)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation as to Whether the Sale of VirtualScopics Inc. to BioTelemetry, Inc. is Fair to Shareholders -- VSCP
ACCESSWIRE - Mon Mar 28, 9:14AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
VSCP: 4.04 (+0.01), BEAT: 18.82 (+0.12)
BioTelemetry, Inc. Signs Definitive Agreement to Acquire VirtualScopics, Inc.
GlobeNewswire - Fri Mar 25, 10:30AM CDT
BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, and VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions, announced today that the two companies have entered into a definitive agreement whereby BioTelemetry will acquire VirtualScopics.
VSCP: 4.04 (+0.01), BEAT: 18.82 (+0.12)
VirtualScopics, Inc. Announces Amendment to Exclusive Marketing Agreement with PPD; Provides Additional Opportunities to Develop New Business Relationships
PR Newswire - Fri Jan 22, 8:00AM CST
VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, today announced that it is amending its alliance agreement with PPD, a contract research organization (CRO), to eliminate the marketing exclusivity portion of the agreement, effective April 11, 2016. The agreement originally signed in 2010, which focused on oncology trials and was later expanded to include other therapeutic areas, restricted VirtualScopics and PPD from co-marketing with each other's competitors. Under the amended agreement, VirtualScopics and PPD will no longer be restricted by exclusive co-marketing. Going forward, they will continue to collaborate on joint imaging projects already underway, as well as those in the current backlog. In addition, they will continue to work together to win new business for their alliance.
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. Promotes Ronald Way to Chief Operating Officer
PR Newswire - Thu Dec 17, 12:02PM CST
VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, today announced that Ronald Way, 60, has been promoted to chief operating officer (COO). Mr. Way joined VirtualScopics in January 2011 as director of operations and was promoted to vice president of operations in August 2014. Mr. Way will be responsible for leading all functions required to deliver superb clinical trial imaging solutions to the company's customers using regulatory compliant processes. Mr. Way has contributed to the increased customer loyalty retention rate over the past few years.
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. Reports 2015 Third Quarter Revenues Increase 18% From Prior Year Period And Company Achieves Positive Adjusted EBITDA
PR Newswire - Thu Oct 29, 3:01PM CDT
VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions, today reported financial results for the third quarter and nine months ended September 30, 2015.
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. to Host Third Quarter 2015 Earnings Conference Call and Webcast Live on Thursday, October 29, 2015
ACCESSWIRE - Wed Oct 28, 3:15PM CDT
ROCHESTER, NY / ACCESSWIRE / October 28, 2015 / VirtualScopics, Inc. (NASDAQ: VSCP) will host a conference call and live webcast to discuss the results of the third quarter 2015, to be held Thursday, October 29, 2015 at 4:30 PM Eastern Time.
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. Schedules Third Quarter 2015 Financial Results Press Release, Conference Call And Webcast
PR Newswire - Wed Oct 14, 7:00AM CDT
VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions, today announced it will report its third quarter 2015 financial results at the 4:00 p.m. ET market close on Thursday, October 29, 2015. Eric T. Converse, president and chief executive officer, and Jim Groff, chief financial officer, will host a conference call and webcast to discuss the company's financial results and provide a business update at 4:30 p.m. ET that afternoon. The conference call and webcast information are as follows:
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. Reports 2015 Second Quarter And Six Months Financial Results; Revenues Increase 14% From 2014 Second Quarter And 17% Above The Six Months Reported In 2014
PR Newswire - Tue Aug 11, 3:01PM CDT
VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions, today reported financial results for the second quarter and six months ended June 30, 2015. Revenues for the second quarter of 2015 rose 14% to $3,019,126 compared to revenues of $2,648,747 for the comparable prior year period. The company reported a net loss for the second quarter of 2015 of $546,992, or $0.20 loss per share, representing a 25% improvement from a net loss of $731,531, or $0.26 loss per share, reported in the second quarter of 2014. Revenues for the first half of 2015 rose 17% to $5,833,568 compared to revenues of $5,001,732 for the comparable prior year period. The company reported a net loss for the first half of 2015 of $1,099,664, or $0.40 loss per share, representing a 20% improvement from a net loss of $1,377,904, or $0.49 loss per share, reported in the first half of 2014.
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. to Host Second Quarter 2015 Earnings Conference Call and Webcast Live on Tuesday, August 11, 2015
ACCESSWIRE - Mon Aug 10, 3:16PM CDT
ROCHESTER, NY / ACCESSWIRE / August 10, 2015 / VirtualScopics, Inc. (NASDAQ: VSCP) will host a conference call and live webcast to discuss the results of the second quarter 2015, to be held Tuesday, August 11, 2015 at 4:30 PM Eastern Time.
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call And Webcast
PR Newswire - Tue Jul 28, 7:00AM CDT
VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, today announced that it will report its second quarter 2015 financial results at the 4:00 p.m. ET market close on Tuesday, August 11, 2015. Eric T. Converse, president and chief executive officer, and Jim Groff, chief financial officer, will host a conference call and webcast to discuss the company's financial results and provide a business update at 4:30 p.m. ET that afternoon. Conference call, webcast and replay information is as follows:
VSCP: 4.04 (+0.01)
VirtualScopics and IXICO Alliance Receive Awards in Oncology and Neurodegenerative Disease
PR Newswire - Mon Jun 29, 7:00AM CDT
VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, along with IXICO plc (AIM: IXI), the brain health company, announced today the alliance has been awarded contracts with two top 15 pharmaceutical companies, one in metastatic solid tumors and one in a rare neurodegenerative disease. IXICO's TrialTracker(TM) digital platform will be deployed in both studies to collect and manage imaging data and in the neurodegeneration study, IXICO's Assessa® digital technology will be used to analyze MRI data collected from patients.
VSCP: 4.04 (+0.01)
Lion Biotechnologies Names Molly Henderson Chief Financial Officer
GlobeNewswire - Mon Jun 08, 7:00AM CDT
Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced the appointment of Molly Henderson, CPA, as chief financial officer, effective immediately.
VSCP: 4.04 (+0.01), LBIO: 7.97 (unch)
VirtualScopics, Inc. Reports Voting Results At Annual Meeting Of Shareholders; All Board Seats Renewed
PR Newswire - Fri Jun 05, 10:00AM CDT
VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, today announced that shareholders have voted for and ratified all three proposals contained in the company's 2015 proxy statement. The outcome of this morning's vote at the Annual Meeting of Shareholders is as follows:
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. To Webcast Annual Meeting Of Shareholders On June 2, 2015; Five Members Of Management To Provide Insight On Operational Excellence And Future Outlook
PR Newswire - Tue May 19, 10:39AM CDT
VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions, today announced it will webcast the 2015 Annual Meeting of Shareholders on Tuesday, June 2, 2015, beginning at 10:00 a.m. The meeting will be held at the Country Club of Rochester, 2935 East Avenue, Rochester, New York, and is open to all VirtualScopics shareholders. Information for this year's Annual Meeting, including the company's Annual Report, Form 10-K and Proxy Statement, can be found on the company's website, www.virtualscopics.com
VSCP: 4.04 (+0.01)
VirtualScopics, Inc. To Present At The 2015 Marcum MicroCap Conference In New York City
PR Newswire - Wed May 13, 4:05PM CDT
VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, announced today that Eric Converse, president and chief executive officer, will be presenting at the Marcum MicroCap Conference, which will be held at the Grand Hyatt Hotel in New York City, on Wednesday, May 27, 2015 at 3:00 p.m. Mr. Converse will also be conducting one-on-one meetings with institutional investors that afternoon and on Thursday, May 28, 2015.
VSCP: 4.04 (+0.01)
(0)
(0)Scroll down for more posts ▼